TMEM209

Across TCGA pan-cancer cohorts, TMEM209 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated TMEM209 data layer compared with 25 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher TMEM209 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated TMEM209 expression acts as an unfavorable survival marker, although some lineages such as COAD and LSCC show a favorable association.

CCRCC, COAD, and UCEC are the cancer types where TMEM209 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	III,IV	0.481	0.872	<.001	67	view →
COAD	DFS	Median	All	1.000	0.890	.024	6	view →
UCEC	OS	Median	All	0.862	0.980	.020	6	view →
PDAC	DFS	Median	II,III,IV	0.693	0.808	.029	6	view →
LSCC	DFS	Median	II,III,IV	0.824	0.557	.029	5	view →
LUAD	OS	Median	II,III,IV	0.911	0.434	.010	4	view →
HNSC	DFS	Median	III,IV	0.693	0.883	.013	3	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

TMEM209–CCRCC (DFS)

Open the CCRCC breakdown →